Drug Profile
Research programme: cancer therapeutics - Evotec SE/Sanofi
Alternative Names: EVT 601; EVT 701; TargetBCDLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)